Purchase Order 75N93019P00780

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation valued at $16,800 on September 6, 2017, with an ultimate completion date of September 14, 2017. Place of performance is Seattle, Washington. The order is for firm fixed-price immunosequencing services. No set-aside category applies.</p>

The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $11,475 on November 2, 2020, for immunosequencing extraction services. Work is performed in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of December 31, 2020. This award was issued to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for immunosequencing services (ImmunoSEQ MMTCRB sequencing) valued at $12,200.00, with award and completion dates of July 12, 2018 and July 12, 2019 respectively.</p> <p>Performance occurs in Seattle, Washington. The order is firm fixed price with no set-aside designation.</p>

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Adaptive Biotechnologies Corporation for DNA extraction services (ImmunoSEQ) valued at $21,225.00 on September 15, 2021. Performance is located in Bethesda, Maryland. The order is priced on a firm fixed-price basis with no small business set-aside. The ultimate completion date is January 7, 2022. This purchase order supports the FY26 UDO Initiative DNA Extraction Services requirement and procures...

<p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $308,400 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide COVID-19 funded immunoseq sequencing services for a COVID-19 research project. The contract will be performed in Seattle, Washington and has a period of performance from November 10, 2022 through May 10, 2023.</p>

The Department of Health and Human Services (HHS) National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $61,150.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for SARS-COV-2 immunosequencing testing services. The contract has a performance period through September 30, 2024 and was awarded on May 7, 2024. Adaptive has previously provided specialized testing and genomic sequencing services to HHS,...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), awarded a $22,280.00 firm fixed price purchase order contract to Adaptive Biotechnologies Corporation (Adaptive) for immunosequencing services. The 1-year contract with a completion date of September 22, 2025 does not have a set-aside designation. Adaptive provides immune-driven medicine products and services, and has previously been awarded...

This is a $12,300 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (Adaptive) for &quot;IMMUNOSEQ MMTCRB SEQUENCING SERVICE&quot;. The contract has an ultimate completion date of December 31, 2023 and was awarded on September 19, 2023 without a set-aside designation. Adaptive, a for-profit organization, has previously...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $20,197.60 firm-fixed-price purchase order for DNA sequencing services to Adaptive Biotechnologies Corporation, doing business as Adaptive. The contract has no set-aside designation and was completed on June 21, 2019. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts from the...

This $19,835 firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (Adaptive) for COVID-19 research and B-cell sequencing services. The contract has a period of performance through March 24, 2021. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts and...